Synairgen used Niche's expertise in the writing of manuscripts to quickly and efficiently develop high-quality documents for submission to relevant journals. Niche's high standards of manuscript preparation and ability to adapt to different journal requirements ensured successful publication. Services included:
"We thank Niche for the enormous contribution they made to moving the Synairgen interferon beta treatment for COVID-19 forwards. We recognise and hugely appreciate the tenacity, adaptiveness dexterity and sheer hard work."
Niche was approached by Synairgen for support in their interferon beta treatment (SNG001) for COVID-19 and COPD during the pandemic. Niche provided support in the development of manuscripts and regulatory documentation for the Phase II data in COVID-19 and COPD, the revolutionary approach to dosing in the home environment and the initiation of a Phase III trial. The Niche team’s expertise in quick and efficient manuscript writing helped Synairgen stay at the forefront of the wave of treating COVID-19.
Niche's work helped Synairgen get recognised by investors worldwide, which at the time, led to the largest fund raising drive ever experienced by the company. This allowed Synairgen the best opportunity to continue testing their product in further clinical trials. Based on the successful Phase II trial with SNG001 for which Niche contributed massively, Synairgen has since been able to initiate a Phase III trial in 17 countries.
Cleothena Enterprises Pty Ltd. is a forward-thinking biotechnology company focused on advancing innovative therapeutic.
read moreAstex employs its proprietary Pyramid™ platform to develop innovative therapies targeting challenging or.
read moreThe British Society for Haematology (BSH), the UK’s largest haematology organisation, promotes excellence within the.
read moreAdaptimmune specialises in developing novel therapies for the treatment of resistant tumour types.
read moreRecardio is a life science company that focuses on drug-based regenerative therapeutic modalities for treatments of.
read moreThe FRAILOMIC initiative was an international research project aimed at improving the understanding, diagnosis, and.
read moreNabriva Therapeutics was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna..
read moreA specialist pharmaceutical company dedicated to HIV medicines and research with an extensive portfolio of prescription.
read moreAssign’s business model relied on bespoke service providers like Niche to deliver essential aspects of their business.
read moreBioKinetic Europe was a fully integrated clinical research organisation with its own purpose-designed clinical.
read moreScandinavian Development Services Life Science was a leading consultancy in the Nordics with regards to regulatory.
read moreGet our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
